These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The reconstruction algorithm used for [ Krohn T; Birmes A; Winz OH; Drude NI; Mottaghy FM; Behrendt FF; Verburg FA Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):662-669. PubMed ID: 27900518 [TBL] [Abstract][Full Text] [Related]
4. Uptake in sympathetic ganglia on Kanthan GL; Hsiao E; Vu D; Schembri GP J Med Imaging Radiat Oncol; 2017 Dec; 61(6):732-738. PubMed ID: 28623872 [TBL] [Abstract][Full Text] [Related]
5. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524 [TBL] [Abstract][Full Text] [Related]
6. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Freitag MT; Radtke JP; Hadaschik BA; Kopp-Schneider A; Eder M; Kopka K; Haberkorn U; Roethke M; Schlemmer HP; Afshar-Oromieh A Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):70-83. PubMed ID: 26508290 [TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132 [TBL] [Abstract][Full Text] [Related]
14. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479 [TBL] [Abstract][Full Text] [Related]
15. Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747 [TBL] [Abstract][Full Text] [Related]
16. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347 [TBL] [Abstract][Full Text] [Related]
17. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748 [TBL] [Abstract][Full Text] [Related]
18. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [ Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369 [TBL] [Abstract][Full Text] [Related]
19. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT. Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003 [TBL] [Abstract][Full Text] [Related]